The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in ...

BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the first subjects have been dosed in a Phase 1b norovirus challenge ...

From classrooms to workplaces, a nasty stomach virus is circulating again, and North Texas doctors say they're bracing for more cases this month. The norovirus, often mistaken for the stomach flu, ...

On April 10 the Washington State Department of Health advised the FDA of a recall of certain shellfish because of norovirus-like illnesses associated with consumption of raw oysters.  The recall ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...

A highly contagious stomach virus with no real treatment is spreading rapidly across the United States. From Aug. 1 through Nov. 13, there were 153 norovirus outbreaks reported in 14 states, according ...

Nearly 100 passengers and four crew members on a Royal Caribbean cruise ship have fallen ill with norovirus, a highly contagious stomach infection. The ship docked in Miami early Monday morning after ...

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion ...